ID-BRIDGETOWER-CAPITAL
15.4.2021 18:02:13 CEST | Business Wire | Press release
BridgeTower Capital, a tokenized global private equity firm, has launched a private Security Token Pre-Offering (STO) culminating 12 months of work to purposefully assemble a team of world-class partners to participate in the blockchain infrastructure and services marketplace in the rapidly growing world of decentralized finance (DeFi).
BridgeTower also announced it has formed a Zurich-based entity to further expand its current offering of blockchain infrastructure products and services.
BridgeTower launched its Private -STO campaign earlier this week, which provides an opportunity for accredited investors to purchase shares in the company in the form of a digital security. BridgeTower has received active participation already and is seeking to raise $200 million in this initial raise.
“We are seeing a global confluence of public and private digital finance markets being fueled by the adoption of blockchain technologies. This is creating unique opportunities for those who can assemble the right team and product offering to navigate the complex international regulatory landscape,” said CEO Cory Pugh.
BridgeTower is bringing a traditional operational business approach to its decentralized “new world” finance business by building recurring revenue and EBITDA growth in addition to providing funding to growth companies with the intent to create increased valuations. BridgeTower’s current blockchain staking product has grown substantially to more than $60 million assets under delegation within two months of launch. BridgeTower will aggressively add self-hosted Nodes over the coming months.
BridgeTower also provides financial, operational, talent acquisition and marketing support for early to mid-stage growth companies. It has made investments in multiple entities in the digital space and will continue to add investments to its portfolio.
BridgeTower has spent the past 12 months assembling global partnerships through its own investment support and from companies that have made significant investments in BridgeTower. A sampling of these partners include:
Algorand
Algorand builds blockchain technology that accelerates the convergence between decentralized and traditional finance by enabling the simple creation of next generation financial products, protocols and exchange of value. Algorand’s technology is well suited for the development of a broader, holistic digital security eco-system for issuers that BridgeTower is focused on.
“We share an aligned vision with BridgeTower where modernized and decentralized infrastructure expands opportunity for participants in the future of financial services. We are excited to support BridgeTower as they allow investors to actually become shareholders in their tokenized private equity firm,” said David Markley, Business Solutions at Algorand. “They have brought together a world class operational team with asset managers who are focused on the convergence of DeFi with traditional finance.”
Securitize
Securitize is reinventing private capital markets by delivering trusted end-to-end security token solutions that leverage leading blockchain technology, which increases access to private markets for eligible investors while simultaneously making them more efficient, compliant, and liquid.
“We’ve worked alongside BridgeTower as their Transfer Agent and Technology partner from early on and are excited by how they’ve approached the DeFi landscape with a regulated product,” said Jamie Finn, Securitize President and Co-Founder. “We are excited to play a meaningful role in bringing the BridgeTower Capital token to market.”
Archax
London-based Archax is the first ever digital securities exchange regulated by the FCA in London. Targeted at institutions, Archax also has its FCA brokerage, and custody permissions. BridgeTower made an earlier investment in Archax because of the company’s market leadership in shaping the landscape of regulated exchanges.
“We are pleased to be working with BridgeTower Capital to prepare them for issuance and we look forward to welcoming them onto the Archax exchange,” said Simon Barnby, Archax Chief Marketing Officer. “Archax has been built to bring credible digital issuances to a global institutional investor community, and BridgeTower’s significant investments in growth companies and blockchain and DeFi, with both debt and equity positions, make it perfectly suited for trading on the Archax global growth market.”
Black Manta
Black Manta’s MiFiD II compliant platform brings issuers and investors together through its licensure by Bafin (Federal Financial Supervisory Authority). BridgeTower recently made a second investment in Black Manta.
“We view companies like BridgeTower as the investment vehicles of the future,” said Christian Plazer, Co-Founder and Managing Partner of BMCP. “BridgeTower has worked hard to develop a host of portfolio companies and partnerships that we are proud to join.”
ABOUT BRIDGETOWER CAPITAL – BridgeTower Capital is a global tokenized private equity firm with a traditional operational business approach towards growth. BridgeTower shareholders have access to opportunities in decentralized finance (DeFi) investments built on blockchain technology. In addition, BridgeTower’s private equity investments in early to mid-stage growth companies provides financial, operational, talent acquisition and marketing support.
Disclaimer
This is not an offer to sale or purchase securities in BridgeTower. Any securities offered by BridgeTower are offered pursuant to a Confidential Private Placement Memorandum to accredited investors only in accordance with an exemption from registration provided by Rule 506(c) of Regulation D of the Securities Act. BridgeTower is not under any obligation to make an offering. Any indications of interest in BridgeTower involves no obligation or commitment of any kind. Past performance is not indicative of future success. Statements about the expected timing, and all other statements in this press release, other than historical facts, constitute forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements speak only as of the date hereof and are based on current expectation and involve a number of assumptions, risks and uncertainties that could cause actual results to differ materially from those projected. A number of the matters discussed herein that are not historical or current facts deal with potential future circumstances and developments that may or may not materialize. This press release speaks only as of its date, and except as required by law, we disclaim any duty to update.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210415005356/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
